Krystal Biotech, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; the filing provides full-year comparisons.
Business context
Krystal is a commercial-stage biotechnology company developing genetic medicines using an engineered HSV-1 vector platform. Its first FDA-approved product, VYJUVEK (beremagene geperpavec-svdt), launched in the U.S. in Q2 2023 for dystrophic epidermolysis bullosa (DEB). The company also operates two commercial-scale manufacturing facilities and is advancing clinical and preclinical pipeline programs.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net product revenue | $50.7 million | $0 |
| Cost of goods sold | $3.1 million | $0 |
| Research and development | $46.4 million | $42.5 million |
| Selling, general and administrative | $98.4 million | $77.7 million |
| Litigation settlement expense | $12.5 million | $25.0 million |
| Operating loss | $(109.7) million | $(145.2) million |
| Gain on sale of priority review voucher | $100.0 million | — |
| Net interest and other income | $22.6 million | $5.2 million |
| Net income (loss) | $10.9 million | $(140.0) million |
| Net cash used in operating activities | $(88.8) million | $(100.6) million |
Reported gross profit on product sales was approximately $47.6 million, or about 94% of revenue; this comparison excludes pre-approval manufacturing costs charged to R&D. FY2023 net income was not driven by operating profitability: it included the one-time $100.0 million voucher-sale gain, while operations remained loss-making.
At year-end, cash and cash equivalents were $358.3 million, short-term investments $173.9 million, and long-term investments $62.0 million. Management’s stated cash, cash equivalents and short-term investments totaled approximately $532.2 million; including long-term investments, these balances totaled about $594.1 million. The company reported $818.4 million in total assets, $39.7 million in total liabilities, and $778.6 million in stockholders’ equity. Lease liabilities were $8.1 million; the filing reports no interest expense in 2023 and does not identify material conventional borrowings.
Operating cash outflow improved by $11.8 million year over year. Investing activities provided $82.6 million, including $100.0 million from the voucher sale, while financing activities provided $202.8 million, principally from a $160.0 million private placement. Year-end accounts receivable was $42.0 million. Management stated that available cash and investments should fund planned operations for at least 12 months from the filing date.
Material changes and developments
- VYJUVEK generated its first commercial revenue in 2023; reported U.S. net product revenue was $50.7 million. The company reported positive coverage policies or decisions for plans covering over 93% of U.S. commercial and Medicaid lives, and patient compliance with weekly treatment was 96% through year-end.
- Net income swung from a $140.0 million loss to $10.9 million income, primarily due to the $100.0 million voucher sale and higher investment income. Operating expenses rose $15.2 million, including higher SG&A for launch and company growth.
- Research and development expenses rose $4.0 million, while SG&A rose $20.7 million. The company paid a further $12.5 million under its PeriphaGen settlement in 2023, compared with $25.0 million in 2022.
- The company completed and qualified its second commercial-scale facility, ASTRA, and began operations there in 2023. Capital expenditures were $11.8 million, down from $53.0 million in 2022.
Outlook, risks and contingencies
- Management expects continued investment in VYJUVEK commercialization, manufacturing and pipeline development; it did not provide quantitative revenue or earnings guidance. Future revenue is expected to fluctuate.
- Krystal expected an EMA decision on the VYJUVEK application in the second half of 2024, a Japan application filing in the second half of 2024 with potential authorization in 2025, and direct European and Japanese launches by 2025. These are forward-looking expectations, not assured outcomes.
- Planned development milestones included starting an approximately 10-patient ophthalmic B-VEC study in the second half of 2024; advancing KB407, KB408 and KB707 clinical studies; resuming KB105 Phase 2 enrollment later in 2024; and reporting KB301 cohort results in the first half of 2024. Timelines and outcomes remain uncertain.
- Key risks include dependence on VYJUVEK’s commercial success, adoption and reimbursement; limited commercial operating history; competition; clinical and regulatory uncertainty; manufacturing and supply continuity; pricing and healthcare-policy changes; and intellectual-property, cybersecurity and international-operation risks.
- Under the PeriphaGen settlement, three additional $12.5 million payments are contingent on cumulative sales reaching $100 million, $200 million and $300 million. No additional accrual was recorded at year-end because achievement was not deemed probable. The filing also lists $16.2 million of future minimum operating lease payments, approximately $1.7 million of CRO/CMO commitments and $8.2 million of remaining ASTRA commitments.
- The financial statements received an unqualified audit opinion; the auditor reported no critical audit matters. Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2023.
Important facts for investors to verify
- Subsequent VYJUVEK sales, patient starts, persistence and net revenue after discounts and rebates; year-end receivables and accrued rebates were material relative to initial sales.
- Whether broad coverage translates into timely reimbursement and sustained uptake, including the effect of the permanent product-specific J-code effective January 1, 2024.
- Progress and final regulatory outcomes for the EU and Japan, and whether pipeline trials meet the company’s stated timelines and demonstrate meaningful safety and efficacy.
- Cash consumption and investment balances against commercialization, R&D and facility costs, as well as potential dilution or financing needs.
- PeriphaGen cumulative-sales milestones and the resulting potential settlement payments.